Presbyopia is an eye condition that causes a reduced ability to see things up close. It occurs when the eye’s lens stops focusing light correctly on the retina and usually develops later in life. The ...

ORLANDO — Qlosi demonstrated consistent pupil size reduction and increasing rates of near visual acuity in patients with presbyopia over 8 days, according to a study. As presbyopia becomes a more ...

Credit: Lenz Therapeutics. Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve ...

The FDA has approved Deseyne contact lenses with extended depth of focus for the correction of presbyopia, according to a ...

LENZ Therapeutics, Inc.'s aceclidine offers superior duration and safety for presbyopia, addressing Vuity's shortcomings and targeting a large, underserved US market. I expect strong initial ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for LNZ100 (aceclidine 1.75% ophthalmic solution) for the treatment of presbyopia. LNZ100 is a single-use, ...

The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only ...

Copenhagen, Denmark: Everybody develops presbyopia as they age – a difficulty in focusing on near objects and text – and often have to resort to reading glasses. However, the solution might be as ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...

PITTSBURGH, June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating ...